Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 24 ... reduced subsequent to metalloprotease-or Src kinase-inhibition, in highly aggressive PC3 prostate cancer cells. These data also show that CXCL12-mediated cellular proliferation requires EGFR ...
2009 NOV 28 ... than I came in," said McElvany, a school superintendent from Wewoka, Okla. treated for prostate cancer. "Few people can say that during cancer treatment. The folks here made me feel like I ...
2009 NOV 24 ... for dimebon (latrepirdine) for Alzheimer's and Huntington diseases and MDV3100 for prostate cancer. A live audio webcast of the presentation will be available on the "Events ...
2009 NOV 26 ... we assessed the effects of piceatannol on the growth of androgen-insensitive DU145 prostate cancer cells at concentrations of 1-10 mu mol/L. Piceatannol reduced the viable numbers and ...
2009 NOV 23 ... According to a study from Hamilton, Canada, "A 49-year-old patient with high-risk prostate cancer presented to a specialist. He was treated with neoadjuvant hormonal therapy for 6 ...
2009 NOV 23 ... the United States, "Despite clear epidemiological and genetic evidence for X-linked prostate cancer risk, all prostate cancer genes identified are ...
2009 NOV 23 ... and molecular evidence suggest potential associations between exercise and prostate cancer risk reduction. We further characterized this relationship by examining exercise and ...
2009 NOV 23 ... of biochemical recurrence and all cause mortality in patients with persistently elevated prostate specific antigen after radical prostatectomy in the Shared Equal Access Regional Cancer ...
2009 NOV 23 ... Systemic delivery of EGF-SubA results in a significant inhibition of human breast and prostate tumor xenografts in mouse models," wrote J.M. Backer and colleagues, SibTech, Inc. ... cytotoxin and endoplasmic reticulum stress-inducing drug synergize to kill cancer cells' new findings in life sciences. According to recent research from the United ...
2009 NOV 23 ... According to a study from the United States, "As the number of prostate cancer survivors increases, urologists must recognize their quality of life impairment. In the ...
2009 NOV 23 ... effects of CCL2 on tumorigenesis and its potential effects on bone metastasis of human prostate cancer, CCL2 was overexpressed into a luciferase-tagged human...
2009 NOV 23 ... evaluation of prostate growth is not necessarily a predictor for the development of prostate cancer. However the study suggests that if a man's PSA level is rising quickly, a prostate ...
2009 NOV 23 ... the United States, "The profound hypogonadism due to androgen deprivation therapy for prostate cancer results in complications such as sexual dysfunction, poor quality of life, vasomotor ...
2009 NOV 23 ... uncertainty about the effect of prostate-specific antigen (PSA) screening on the rate of prostate cancer death, there is little uncertainty about its effect on the rate of...
2009 NOV 23 ... Investigators publish new data in the report 'Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation ...
2009 NOV 25 ... Insulation, "The effects of nanosecond pulsed electric fields (nsPEF) on the human prostate cancer cell line LNCaP was investigated for changes in protein and DNA concentrations as well ...
2009 NOV 23 ... Investigators publish new data in the report 'Breast, colorectal and prostate cancer screening for cancer survivors and non-cancer patients in community practices.' ...
2009 NOV 23 ... chordomas, chondrosarcomas and meningiomas as well as tumors of the salivary glands and prostate carcinomas. Brain tumors such as glioblastomas and low-grade astrocytomas will also be ... for Heavy Ion Research in Darmstadt and the Department of Medical Physics at the German Cancer Research Center (DKFZ) in Heidelberg, as well as the Rossendorf Research Center in ...
2009 NOV 23 ... Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 ...
